Table 2 Correlation of ATF3 mRNA expression and clinical prognosis in HCC with different clinicopathological factors
Clinicopathological characteristics | Overall survival (OS) | Progression-free survival (PFS) | ||||
|---|---|---|---|---|---|---|
N | Hazard ratio (HR) | P-value | N | Hazard ratio (HR) | P-value | |
Sex | ||||||
Female | 118 | 1.71(0.98–2.98) | 5.60E−02 | 121 | 1.44 (0.87–2.41) | 1.60E−01 |
Male | 246 | 0.52(0.33–0.83) | 3.90E−03 | 250 | 0.61 (0.42–0.89) | 9.00E−03 |
Race | ||||||
White | 181 | 0.67(0.41–1.09) | 1.10E−01 | 184 | 1.41 (0.85–2.32) | 1.80E−01 |
Asian | 155 | 0.43(0.24–0.77) | 3.80E−03 | 157 | 0.54(0.33–0.88) | 1.20E−02 |
Stage | ||||||
1 | 170 | 2(1.02–3.91) | 4.00E−02 | 171 | 1.51 (0.9–02.52) | 1.10E−01 |
1 + 2 | 253 | 0.69 (0.4–1.17) | 1.60E−01 | 256 | 0.73 (0.48–1.12) | 1.50E−01 |
2 | 83 | 0.49(0.21–1.14) | 9.00E−02 | 84 | 0.53 (0.3–0.96) | 3.40E−02 |
2 + 3 | 166 | 0.37(0.23–0.61) | 3.50E−05 | 170 | 0.66 (0.44–1) | 4.60E−02 |
3 | 83 | 0.32(0.18–0.6) | 1.50E−04 | 85 | 0.81 (0.46–1.44) | 4.80E−01 |
3 + 4 | 87 | 0.36(0.2–0.64) | 3.50E−04 | 90 | 0.83 (0.48–1.45) | 5.10E−01 |
4 | 4 | 5 | ||||
Grade | ||||||
1 | 55 | 0.49(0.18–1.35) | 1.60E−01 | 55 | 0.76(0.31–1.89) | 5.50E−01 |
2 | 174 | 0.3(0.18–0.52) | 4.30E−06 | 177 | 0.540.34–0.86) | 7.80E−03 |
3 | 128 | 0.31(0.71–2.42) | 3.80E−01 | 121 | 1.2 (0.72–2) | 4.90E−01 |
4 | 12 | 12 | ||||
AJCC stage T | ||||||
1 | 180 | 1.89(1.01–3.55) | 4.40E−02 | 181 | 1.49(0.91–2.45) | 1.10E−01 |
2 | 90 | 0.41(0.19–0.89) | 2.00E−02 | 92 | 0.68 (0.38–1.2) | 1.80E−01 |
3 | 78 | 0.32(0.17–0.6) | 1.90E−04 | 80 | 0.79 (0.43–1.45) | 4.40E−01 |
4 | 13 | 13 | ||||
Vascular invasion | ||||||
None | 203 | 0.63(0.37–1.06) | 8.10E−02 | 205 | 0.7 (0.43–1.15) | 1.60E−01 |
Micro | 90 | 0.46(0.17–1.21) | 1.10E−01 | 90 | 0.46(0.17–1.21) | 1.10E−01 |
Macro | 16 | 16 | ||||
Sorafenib treatment | ||||||
Treated | 29 | 0.28(0.08–0.95) | 3.00E−02 | 30 | 0.25 (0.09–0.66) | 2.50E−03 |
Alcohol consumption | ||||||
Yes | 115 | 0.36(0.19–0.38) | 1.00E−03 | 117 | 0.53 (0.29–0.94) | 2.80E−02 |
No | 202 | 0.64(0.37–1.1) | 1.10E−01 | 205 | 0.83 (0.53–1.29) | 4.10E−01 |
Hepatitis virus | ||||||
Yes | 150 | 0.76(0.91–3.43) | 9.10E−02 | 143 | 1.37 (0.87–2.18) | 1.80E−01 |
None | 167 | 0.59(0.38–0.94) | 2.30E−02 | 169 | 0.49 (0.28–0.83) | 7.20E−03 |